Who are HPC, Cord Blood's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Platelet Rich Plasma (PRP), RAK therapy, Concentrated Bone Marrow Aspirate Injection, Leukocyte rich platelet rich plasma, Fibroblasts and keratinocytes.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hpc-cord-blood.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HPC, Cord Blood — Competitive Intelligence Brief

HPC, Cord Blood (HPC, Cord Blood) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy; hematopoietic stem cell transplant. Area: Oncology; Hematology.

marketed Cell therapy; hematopoietic stem cell transplant Oncology; Hematology Biologic Live · refreshed every 30 min

Target snapshot

HPC, Cord Blood (HPC, Cord Blood) — National Marrow Donor Program. HPC (hematopoietic progenitor cells) from umbilical cord blood engraft in the bone marrow and reconstitute the hematopoietic and immune systems.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HPC, Cord Blood TARGET	HPC, Cord Blood	National Marrow Donor Program	marketed	Cell therapy; hematopoietic stem cell transplant
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
Concentrated Bone Marrow Aspirate Injection	Concentrated Bone Marrow Aspirate Injection	Hospital for Special Surgery, New York	marketed	Autologous stem cell therapy
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Fibroblasts and keratinocytes	Fibroblasts and keratinocytes	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	marketed	Cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy; hematopoietic stem cell transplant class)

National Marrow Donor Program · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HPC, Cord Blood — Competitive Intelligence Brief. https://druglandscape.com/ci/hpc-cord-blood. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab